S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.28 (+2.52%)
MSFT   332.34 (-1.27%)
FB   327.82 (-3.02%)
GOOGL   2,856.00 (-1.88%)
AMZN   3,516.36 (-1.27%)
TSLA   1,137.66 (+0.06%)
NVDA   324.88 (-2.66%)
BABA   127.76 (-2.93%)
NIO   39.26 (-2.97%)
CGC   10.54 (-4.70%)
AMD   157.79 (-2.54%)
GE   95.64 (-2.80%)
MU   85.19 (-1.10%)
T   22.82 (-4.48%)
F   19.30 (-1.88%)
DIS   144.33 (-2.35%)
ACB   6.29 (-2.33%)
AMC   34.34 (-6.79%)
PFE   53.95 (+2.96%)
BA   196.42 (-1.05%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.28 (+2.52%)
MSFT   332.34 (-1.27%)
FB   327.82 (-3.02%)
GOOGL   2,856.00 (-1.88%)
AMZN   3,516.36 (-1.27%)
TSLA   1,137.66 (+0.06%)
NVDA   324.88 (-2.66%)
BABA   127.76 (-2.93%)
NIO   39.26 (-2.97%)
CGC   10.54 (-4.70%)
AMD   157.79 (-2.54%)
GE   95.64 (-2.80%)
MU   85.19 (-1.10%)
T   22.82 (-4.48%)
F   19.30 (-1.88%)
DIS   144.33 (-2.35%)
ACB   6.29 (-2.33%)
AMC   34.34 (-6.79%)
PFE   53.95 (+2.96%)
BA   196.42 (-1.05%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.28 (+2.52%)
MSFT   332.34 (-1.27%)
FB   327.82 (-3.02%)
GOOGL   2,856.00 (-1.88%)
AMZN   3,516.36 (-1.27%)
TSLA   1,137.66 (+0.06%)
NVDA   324.88 (-2.66%)
BABA   127.76 (-2.93%)
NIO   39.26 (-2.97%)
CGC   10.54 (-4.70%)
AMD   157.79 (-2.54%)
GE   95.64 (-2.80%)
MU   85.19 (-1.10%)
T   22.82 (-4.48%)
F   19.30 (-1.88%)
DIS   144.33 (-2.35%)
ACB   6.29 (-2.33%)
AMC   34.34 (-6.79%)
PFE   53.95 (+2.96%)
BA   196.42 (-1.05%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.28 (+2.52%)
MSFT   332.34 (-1.27%)
FB   327.82 (-3.02%)
GOOGL   2,856.00 (-1.88%)
AMZN   3,516.36 (-1.27%)
TSLA   1,137.66 (+0.06%)
NVDA   324.88 (-2.66%)
BABA   127.76 (-2.93%)
NIO   39.26 (-2.97%)
CGC   10.54 (-4.70%)
AMD   157.79 (-2.54%)
GE   95.64 (-2.80%)
MU   85.19 (-1.10%)
T   22.82 (-4.48%)
F   19.30 (-1.88%)
DIS   144.33 (-2.35%)
ACB   6.29 (-2.33%)
AMC   34.34 (-6.79%)
PFE   53.95 (+2.96%)
BA   196.42 (-1.05%)
NYSEAMERICAN:PTN

Palatin Technologies Stock Competitors

$0.64
-0.21 (-24.95%)
(As of 11/30/2021 02:06 PM ET)
Add
Compare
Today's Range
$0.60
$0.85
50-Day Range
N/A
52-Week Range
$0.33
$1.30
Volume
695,756 shs
Average Volume
4.10 million shs
Market Capitalization
$148.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.1

Palatin Technologies (NYSEAMERICAN:PTN) Vs. TBPH, VERU, EPIX, IMRX, FULC, DMCAF, PHAT, CMRX, IVA, and ORIC

Should you be buying Palatin Technologies stock or one of its competitors? The main competitors of Palatin Technologies include Theravance Biopharma (TBPH), Veru (VERU), ESSA Pharma (EPIX), Immuneering (IMRX), Fulcrum Therapeutics (FULC), DiaMedica Therapeutics (DMCAF), Phathom Pharmaceuticals (PHAT), Chimerix (CMRX), Inventiva (IVA), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical preparations" industry.

Palatin Technologies vs.

Veru (NASDAQ:VERU) and Palatin Technologies (NYSEAMERICAN:PTN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Veru currently has a consensus price target of $19.60, indicating a potential upside of 169.23%. Palatin Technologies has a consensus price target of $3.33, indicating a potential upside of 420.75%. Given Palatin Technologies' higher possible upside, analysts plainly believe Palatin Technologies is more favorable than Veru.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Palatin Technologies
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Palatin Technologies had 2 more articles in the media than Veru. MarketBeat recorded 6 mentions for Palatin Technologies and 4 mentions for Veru. Palatin Technologies' average media sentiment score of 0.28 beat Veru's score of 0.09 indicating that Palatin Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veru
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Palatin Technologies
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

30.6% of Veru shares are held by institutional investors. Comparatively, 9.8% of Palatin Technologies shares are held by institutional investors. 24.6% of Veru shares are held by insiders. Comparatively, 8.2% of Palatin Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Veru has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Palatin Technologies received 184 more outperform votes than Veru when rated by MarketBeat users. Likewise, 73.69% of users gave Palatin Technologies an outperform vote while only 71.88% of users gave Veru an outperform vote.

CompanyUnderperformOutperform
VeruOutperform Votes
253
71.88%
Underperform Votes
99
28.13%
Palatin TechnologiesOutperform Votes
437
73.69%
Underperform Votes
156
26.31%

Veru has higher revenue and earnings than Palatin Technologies. Veru is trading at a lower price-to-earnings ratio than Palatin Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million13.74-$18.97 million-$0.01-732.27
Palatin Technologies$120 thousand1,237.12-$33.60 million-$0.14-4.58

Palatin Technologies has a net margin of 0.00% compared to Veru's net margin of -0.25%. Veru's return on equity of -7.62% beat Palatin Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Veru -0.25% -7.62% -6.11%
Palatin Technologies N/A -52.22% -39.98%

Summary

Palatin Technologies beats Veru on 9 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSEAMERICAN and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Palatin Technologies (NYSEAMERICAN:PTN) vs. Its Competitors

TypePalatin TechnologiesPharmaceutical IndustryMedical SectorNYSEAMERICAN Exchange
Market Cap$148.45M$5.83B$4.94B$648.58M
Dividend YieldN/A2.59%2.04%2.89%
P/E Ratio-4.5810.3919.397.90
Price / Sales1,237.12568.592,542.81170.16
Price / CashN/A25.0141.4114.75
Price / Book2.9210.879.543.88
Net Income-$33.60M$95.45M$95.31M-$14.93M
7 Day PerformanceN/A-2.73%111.29%-4.92%
1 Month PerformanceN/A-9.81%106.84%N/A
1 Year Performance45.44%15.97%161.16%45.37%

Palatin Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TBPH
Theravance Biopharma
2.1115 of 5 stars
$8.00
-2.5%
$10.88
-35.9%
-52.5%$589.58M$71.86M-2.33359
VERU
Veru
2.1181 of 5 stars
$7.33
-2.2%
$19.60
-167.4%
+143.6%$585.33M$42.59M-732.27339Upcoming Earnings
EPIX
ESSA Pharma
2.0333 of 5 stars
$13.26
-2.1%
$34.67
-161.4%
+98.2%$583.18MN/A-13.6725Short Interest ↓
Analyst Revision
News Coverage
IMRX
Immuneering
1.6265 of 5 stars
$22.47
-9.0%
$43.67
-94.3%
N/A$582.87MN/A0.002,021Gap Down
FULC
Fulcrum Therapeutics
2.2998 of 5 stars
$14.36
-0.2%
$36.33
-153.0%
+24.2%$582.30M$8.82M-6.1173Short Interest ↑
Gap Up
DMCAF
DiaMedica Therapeutics
0.7998 of 5 stars
$3.63
-3.9%
N/A-93.3%$570.42MN/A0.00N/ANews Coverage
PHAT
Phathom Pharmaceuticals
2.3665 of 5 stars
$18.05
-3.8%
$60.25
-233.8%
-56.5%$567.04MN/A-3.9955News Coverage
CMRX
Chimerix
2.0381 of 5 stars
$6.34
-7.6%
$18.00
-183.9%
+53.8%$550.69M$5.37M-3.4854Gap Up
IVA
Inventiva
1.4798 of 5 stars
$13.51
-1.0%
$42.00
-210.9%
+4.3%$550.40M$430K0.0088Gap Up
High Trading Volume
ORIC
ORIC Pharmaceuticals
2.4664 of 5 stars
$13.79
-2.3%
$26.33
-91.0%
-57.6%$543.08MN/A-5.9261
GTHX
G1 Therapeutics
1.8531 of 5 stars
$12.72
-1.4%
$45.67
-259.0%
-12.3%$540.85M$45.28M-3.90122
BYSI
BeyondSpring
1.7314 of 5 stars
$13.51
-3.7%
$58.75
-334.9%
+16.3%$528.38M$180K-7.0091News Coverage
Gap Up
PYR
PyroGenesis Canada
0 of 5 stars
$3.08
-4.9%
N/AN/A$526.06M$13.27M0.002,020Short Interest ↑
News Coverage
ANIP
ANI Pharmaceuticals
2.4548 of 5 stars
$40.89
-2.5%
$68.33
-67.1%
+42.2%$521.35M$208.48M-22.34369Short Interest ↓
Gap Down
PHAR
Pharming Group
0.6949 of 5 stars
$8.03
-3.4%
N/AN/A$519.35M$212.10M0.00262Analyst Downgrade
News Coverage
AVDL
Avadel Pharmaceuticals
1.8714 of 5 stars
$8.85
-5.4%
$16.50
-86.4%
+24.9%$518.79M$22.33M-7.832,020Short Interest ↑
KPTI
Karyopharm Therapeutics
2.24 of 5 stars
$6.80
-0.7%
$14.83
-118.1%
-54.8%$513.74M$108.08M-2.46432News Coverage
OCUL
Ocular Therapeutix
2.0398 of 5 stars
$6.64
-1.8%
$24.00
-261.4%
-62.6%$508.69M$17.40M-3.44181
GRCL
Gracell Biotechnologies
1.4465 of 5 stars
$7.53
-3.7%
$34.50
-358.2%
N/A$508.28MN/A0.002,020Gap Down
BPMUF
Basilea Pharmaceutica
0.9248 of 5 stars
$47.00
-0.0%
N/AN/A$504.78M$136.11M0.00157High Trading Volume
NKTX
Nkarta
2.3531 of 5 stars
$15.16
-0.6%
$70.80
-367.0%
-55.0%$499.51M$120K-6.1195
ICPT
Intercept Pharmaceuticals
2.2426 of 5 stars
$16.81
-2.3%
$29.67
-76.5%
-55.9%$496.74M$312.69M-5.19498Gap Up
PLRX
Pliant Therapeutics
2.0333 of 5 stars
$13.76
-2.3%
$47.40
-244.5%
-57.4%$495.90M$41.82M-5.3578Analyst Downgrade
DCPH
Deciphera Pharmaceuticals
2.4548 of 5 stars
$8.43
-8.7%
$35.00
-315.2%
-87.7%$492.99M$42.09M-1.78350Gap Down
Trading Halted
SMMT
Summit Therapeutics
1.1331 of 5 stars
$5.01
-0.8%
N/A+16.4%$489.55M$20.17M-5.4580
CALT
Calliditas Therapeutics AB (publ)
1.7581 of 5 stars
$18.37
-3.8%
$52.00
-183.1%
-46.7%$480.74M$90K-8.7546Short Interest ↓
Positive News
Gap Up
VSTM
Verastem
2.0648 of 5 stars
$2.63
-1.5%
$6.33
-140.8%
+30.2%$479.15M$88.52M-5.9849
MRSN
Mersana Therapeutics
1.5864 of 5 stars
$6.65
-0.2%
$26.80
-303.0%
-73.6%$478.20M$830K-3.11110
BLU
BELLUS Health
2.3264 of 5 stars
$5.99
-1.7%
$12.00
-100.3%
+93.1%$469.26M$10K-7.3032Short Interest ↑
GERN
Geron
1.7998 of 5 stars
$1.46
-0.3%
$5.50
-278.0%
-22.5%$468.44M$250K-4.4154
AKBA
Akebia Therapeutics
1.8581 of 5 stars
$2.67
-1.9%
$9.00
-237.1%
-22.7%$467.14M$295.31M-1.41380
RIGL
Rigel Pharmaceuticals
1.9931 of 5 stars
$2.71
-0.4%
$9.50
-250.6%
-13.2%$463.43M$108.62M-30.11169
SPRO
Spero Therapeutics
2.4414 of 5 stars
$14.32
-0.6%
$52.33
-265.5%
-13.9%$462.88M$9.33M-5.3689
PHVS
Pharvaris
1.8081 of 5 stars
$14.50
-2.3%
$47.50
-227.6%
N/A$461.68MN/A0.0014Short Interest ↓
Gap Up
AADI
Aadi Bioscience
1.825 of 5 stars
$22.03
-0.1%
$43.75
-98.6%
+81.5%$460.21M$15M-1.6512Gap Down
FLXN
Flexion Therapeutics
2.267 of 5 stars
$9.12
-0.0%
$12.43
-36.3%
N/A$458.93M$85.55M-4.54257
ALBO
Albireo Pharma
2.0798 of 5 stars
$23.53
-3.1%
$79.80
-239.1%
-37.2%$453.66M$8.31M-9.0890
EVLO
Evelo Biosciences
1.9948 of 5 stars
$8.37
-2.0%
$21.92
-161.8%
+57.7%$447.46MN/A-3.502,018
RYTM
Rhythm Pharmaceuticals
1.8564 of 5 stars
$8.77
-0.9%
$36.33
-314.3%
-69.8%$440.85MN/A-6.8090News Coverage
Gap Down
MIRM
Mirum Pharmaceuticals
2.6864 of 5 stars
$14.38
-9.2%
$47.60
-231.0%
-41.3%$440.60MN/A-2.3568Insider Buying
Short Interest ↓
News Coverage
Gap Up
OMER
Omeros
1.9114 of 5 stars
$7.02
-0.7%
$30.33
-332.1%
-39.8%$439.05M$73.81M-3.53277
ALDX
Aldeyra Therapeutics
1.9931 of 5 stars
$7.54
-5.0%
$26.25
-248.1%
+3.2%$438.00MN/A-6.5615Options Volume
News Coverage
THRN
Thorne Healthtech
2.075 of 5 stars
$8.30
-1.1%
$11.50
-38.6%
N/A$436.12MN/A0.002,021
CTMX
CytomX Therapeutics
1.9598 of 5 stars
$6.60
-1.2%
$13.00
-97.0%
-12.1%$430.65M$100.36M-5.41145
VACC
Vaccitech
1.825 of 5 stars
$12.26
-1.0%
$24.67
-101.2%
N/A$427.29M$4.82M0.002,021Positive News
LGVN
Longeveron
0.3333 of 5 stars
$22.21
-18.2%
N/AN/A$424.66M$5.63M0.0012
NBRV
Nabriva Therapeutics
2.0414 of 5 stars
$0.78
-8.4%
$6.00
-669.2%
+95.3%$423.67M$5.03M-0.3672Analyst Downgrade
Short Interest ↑
PRVB
Provention Bio
2.4123 of 5 stars
$6.68
-1.8%
$17.75
-165.7%
-58.4%$423.35MN/A-3.3659
ABUS
Arbutus Biopharma
2.0981 of 5 stars
$3.11
-1.0%
$7.25
-133.1%
-27.6%$420.69M$6.91M-3.4277
FHTX
Foghorn Therapeutics
2.1781 of 5 stars
$11.31
-9.5%
$24.00
-112.2%
-40.9%$419.49M$430K0.0095Analyst Downgrade
News Coverage
Gap Down
This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.